Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility

被引:76
作者
Zhang, SL
DuBois, W
Ramsay, ES
Bliskovski, V
Morse, HC
Taddesse-Heath, L
Vass, WC
DePinho, RA
Mock, BA
机构
[1] NCI, Genet Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Cellular Oncol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
[3] NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA
[4] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1128/MCB.21.1.310-318.2001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The susceptibility of BALB/c mice to pristane-induced plasmacytomas is a complex genetic trait involving multiple loci, while DBA/2 and C57BL/6 strains are genetically resistant to the plasmacytomagenic effects of pristane. In this model system for human B-cell neoplasia, one of the BALB/c susceptibility and modifier loci, Pctr1, was mapped to a 5.7-centimorgan (cM) chromosomal region that included Cdkn2a, which encodes p16(INK4a) and p19(ARF), and the coding sequences for the BALB/c p16(INK4a) and p19(ARF) alleles were found to be polymorphic with respect to their resistant Pctr1 counterparts in DBA/2 and C57BL/6 mice (45), In the present study, alleles of Pctr1, Cdkn2a, and D4Mit15 from a resistant strain (BALB/cDAG) carrying DBA/2 chromatin were introgressively backcrossed to the susceptible BALB/c strain. The resultant C.DAG-Pctr1 Cdkn2a D4Mit15 congenic was more resistant to plasmacytomagenesis than BALB/c, thus narrowing Pctr1 to a 1.5-cM interval, Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. Biological assays of the p16(INK4a) and p19(ARF) alleles from BALB/c and DBA/2 indicated that the BALB/c p16(INK4a) allele was less active than its DBA/2 counterpart in inducing growth arrest of mouse plasmacytoma cell lines and preventing ras-induced transformation of NIH 3T3 cells, while the two p19(ARF) alleles displayed similar potencies in both assays. We propose that the BALB/c susceptibility/modifier locus, Pctr1, is an "efficiency" allele of the p16(INK4a) gene.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 47 条
[1]  
Ahmad N N, 1999, Ophthalmic Genet, V20, P225, DOI 10.1076/opge.20.4.225.2269
[2]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[3]   An acute phase response factor NF-kappa B site downstream of the junB gene that mediates responsiveness to interleukin-6 in a murine plasmacytoma [J].
Brown, RT ;
Ades, IZ ;
Nordan, RP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (52) :31129-31135
[4]   Association of the α-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation [J].
Carter, AM ;
Catto, AJ ;
Grant, PJ .
CIRCULATION, 1999, 99 (18) :2423-2426
[5]   RAPID INDUCTION OF IGM-SECRETING MURINE PLASMACYTOMAS BY PRISTANE AND AN IMMUNOGLOBULIN HEAVY-CHAIN PROMOTER ENHANCER-DRIVEN C-MYC/V-HA-RAS RETROVIRUS [J].
CLYNES, R ;
WAX, J ;
STANTON, LW ;
SMITHGILL, S ;
POTTER, M ;
MARCU, KB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :6067-6071
[6]   Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis [J].
Cormier, RT ;
Hong, KH ;
Halberg, RB ;
Hawkins, TL ;
Richardson, P ;
Mulherkar, R ;
Dove, WF ;
Lander, ES .
NATURE GENETICS, 1997, 17 (01) :88-91
[7]   GENETIC IDENTIFICATION OF MOM-1, A MAJOR MODIFIER LOCUS AFFECTING MIN-INDUCED INTESTINAL NEOPLASIA IN THE MOUSE [J].
DIETRICH, WF ;
LANDER, ES ;
SMITH, JS ;
MOSER, AR ;
GOULD, KA ;
LUONGO, C ;
BORENSTEIN, N ;
DOVE, W .
CELL, 1993, 75 (04) :631-639
[8]   Germline CDKN2A mutation implicated in predisposition to multiple myeloma [J].
Dilworth, D ;
Liu, L ;
Stewart, AK ;
Berenson, JR ;
Lassam, N ;
Hogg, D .
BLOOD, 2000, 95 (05) :1869-1871
[9]   Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells [J].
Drexler, HG .
LEUKEMIA, 1998, 12 (06) :845-859
[10]  
Farker K, 2000, INT J CLIN PHARM TH, V38, P30